Skip to nav Skip to content
Jonathan  Metts

Jonathan Metts, MD

Specialty: Medical Oncology

Program: Sarcoma

Language(s): English

  • Overview

    Cancer Focus:
    Osteosarcoma, Sarcoma

    Dr. Metts specializes in the care of adolescents and young adults with sarcoma. He received his MD degree from the University of South Carolina School of Medicine. He completed a Pediatric Residency at the University South Florida Morsani School of Medicine followed by a Pediatric Hematology/Oncology Fellowship at Emory University School of Medicine and the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta. Dr. Metts joins us from Johns Hopkins All Children’s Hospital in St. Petersburg, Florida where he continues clinical care and research as a part-time Assistant Professor in the Cancer and Blood Disorders Institute. Dr. Metts research interests include novel therapies and clinical trials for patients with sarcomas and other tumors as well as cellular therapy for pediatric solid tumors, including tumor infiltrating lymphocyte therapy. Dr. Metts is Co-Chairman of the National Pediatric Cancer Foundation's Sunshine Project, a clinical trials and translational research consortium comprised of leading pediatric oncology institutions across the United States with a mission to identify more effective and less toxic treatments for children with cancer.    

  • Participating Trials

    Clinical Trial 20339
    Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
    Condition: Sarcoma
    Intervention: Actinomycin D (Dactinomycin); Adriamycin (doxorubicin); Ifosfamide (); Navelbine (Vinorelbine); Radiotherapy (); Vincristine (); Vinorelbine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); etoposide ()
    Status: Open

    Clinical Trial 22170
    Feasibility of Generating Novel Translational and Therapeutic Strategies based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
    Condition: Multiple
    Intervention: Not Applicable ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Reed DR, Tulpule A, Metts J, Trucco M, Robertson-Tessi M, O'Donohue TJ, Iglesias-Cardenas F, Isakoff MS, Mauguen A, Shukla N, Dela Cruz FS, Tap W, Kentsis A, Morris CD, Hameed M, Honeyman JN, Behr GG, Sulis ML, Ortiz MV, Slotkin E. Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials. J Clin Oncol. 2024 Jun. Pubmedid: 38843482.
    • Metts J, Xue W, Gao Z, Oberoi S, Weiss AR, Venkatramani R, Harrison DJ. Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2024 Jul.71(7):e31009. Pubmedid: 38627882. Pmcid: PMC11180298.
    • Farrar A, Blanco P, Fabbrini A, Armstrong L, Metts J, Monforte H, Karjoo S, Danielson P, Wilsey M. Appendiceal mucinous neoplasm in adolescence: Diagnosis, management, and surveillance. JPGN Rep. 2024 Feb.5(1):66-69. Pubmedid: 38545266. Pmcid: PMC10964329.
    • Cho S, Miller A, Mosha M, McNerney KO, Metts J. Clinical Trials on Cellular Therapy for Children and Adolescents With Cancer: A 15-Year Trend in the United States. Cureus. 2023 Oct.15(10):e47885. Pubmedid: 38021600. Pmcid: PMC10681796.
    • Welch DL, Fridley BL, Cen L, Teer JK, Yoder SJ, Pettersson F, Xu L, Cheng CH, Zhang Y, Alexandrow MG, Xiang S, Robertson-Tessi M, Brown JS, Metts J, Brohl AS, Reed DR. Modeling phenotypic heterogeneity towards evolutionarily inspired osteosarcoma therapy. Sci Rep. 2023 Nov.13(1):20125. Pubmedid: 37978271. Pmcid: PMC10656496.
    • Metts J, Xue W, Gao Z, Ermoian R, Bradley JA, Arnold MA, Dasgupta R, Venkatramani R, Walterhouse D. Survival of patients with orbital and eyelid rhabdomyosarcoma treated on Children's Oncology Group studies from 1997 to 2013: A report from the Children's Oncology Group. Cancer. 2023 Jun.129(11):1735-1743. Pubmedid: 36857314. Pmcid: PMC10288338.
    • Shaw PH, Metts J, Amankwah E, Eslin DE, Bradfield S, Slayton WB, Hays B, Calkins B, Rico J, Krischer J. Trends in Pediatric Cancer Care in Florida From 1981-2020: Changing Patterns in a Growing and Increasingly Diverse Population. Cureus. 2023 Feb.15(2):e35061. Pubmedid: 36938203. Pmcid: PMC10023130.
    • Metts JL, Trucco M, Weiser DA, Thompson P, Sandler E, Smith T, Crimella J, Sansil S, Thapa R, Fridley BL, Llosa N, Badgett T, Gorlick R, Reed D, Gill J. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. Cancer Med. 2023 Feb.12(4):4270-4281. Pubmedid: 36151773. Pmcid: PMC9972017.
    • Morris D, Gonzalez R, Cook J, Metts J, Shaw P. Gastrointestinal Complications of Intra-Abdominal Desmoid Tumors: A Case Report and Review of the Literature. Case Rep Oncol. 2022 May.15(2):515-521. Pubmedid: 35813700. Pmcid: PMC9209997.
    • Metts J, Harrington B, Salman E, Bradfield SM, Flanary J, Mosha M, Amankwah E, Stapleton S. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors. Childs Nerv Syst. 2022 May.38(5):919-928. Pubmedid: 35260913.
    • Hensel J, Metts J, Gupta A, Ladle BH, Pilon-Thomas S, Mullinax J. Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. Cancer J. 2022 Jul.28(4):322-327. Pubmedid: 35880942. Pmcid: PMC9847472.
    • Metts J, Russell T, Reed D, Trucco M. A Proposed Trial Design for the Treatment of Widely Metastatic Ewing Sarcoma Inspired by Evolutionary Dynamics. Cancers (Basel). 2022 Jan.14(3). Pubmedid: 35159003. Pmcid: PMC8833360.
    • Gaefke CL, Metts J, Imanirad D, Nieves D, Terranova P, Dell'Orso G, Gambineri E, Miano M, Lockey RF, Walter JE, Westermann-Clark E. Case Report: A Novel Pathogenic Missense Mutation in FAS: A Multi-Generational Case Series of Autoimmune Lymphoproliferative Syndrome. Front Pediatr. 2021 Mar.9:624116. Pubmedid: 33816397. Pmcid: PMC8012668.
    • Wang Z, Mi T, Bradley HL, Metts J, Sabnis H, Zhu W, Arbiser J, Bunting KD. Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia. Antioxidants (Basel). 2021 Jun.10(6). Pubmedid: 34203664. Pmcid: PMC8232307.
    • Westermann-Clark E, Meehan CA, Meyer AK, Dasso JF, Amre D, Ellison M, Patel B, Betensky M, Hauk CI, Mayer J, Metts J, Leiding JW, Sriaroon P, Kumar A, Ayala I, Walter JE. Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort. Front Immunol. 2021 Apr.12:649182. Pubmedid: 33968040. Pmcid: PMC8100326.
    • Sabnis HS, Minson KA, Monroe C, Allen K, Metts JL, Cooper TM, Woods WG, Castellino SM, Keller FG. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes. Leuk Res. 2020 Sep.96:106421. Pubmedid: 32683126.
    • Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun.126(11):2577-2587. Pubmedid: 32176331. Pmcid: PMC7318114.
    • Metts JL, Park SI, Briones MA, Keller FG. Hemophagocytic Lymphohistiocytosis Secondary to T Cell/Histiocyte-rich Large B Cell Lymphoma in an Adolescent Male. Pediatr Dev Pathol. 2019 May.21(1):95-99. Pubmedid: 29187030.
    • Metts JL, Alazraki AL, Clark D, Amankwah EK, Wasilewski-Masker KJ, George BA, Olson TA, Cash T. Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas. Pediatr Blood Cancer. 2018 Sep.65(9):e27246. Pubmedid: 29770997.
    • Metts JL, Park SI, Soares BP, Fong C, Biegel JA, Goldsmith KC. Concurrent myeloid sarcoma, atypical teratoid/rhabdoid tumor, and hypereosinophilia in an infant with a germline SMARCB1 mutation. Pediatr Blood Cancer. 2017 Sep.64(9). Pubmedid: 28111898.
    • Metts J, Bradley HL, Wang Z, Shah NP, Kapur R, Arbiser JL, Bunting KD. Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. Sci Rep. 2017 Jun.7(1):4447. Pubmedid: 28667329. Pmcid: PMC5493614.
  • Grants

    Title: Feasibility of Generating Novel Translational and Therapeutic Strategies based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board; pedsETB
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI: Metts, J., CO-PI: Robertson-Tessi, M., CO-PI: Anderson, A., CO-PI: Brown, J., CO-PI: Marusyk, A.
    Title: The Sunshine Project 2024-2028
    Sponsor: National Pediatric Cancer Foundation
    PI: Metts, J.
  • Patient Comments

    Overall Satisfaction

    5

    16 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor